期刊文献+

川芎嗪对大鼠灌服环孢素A药代动力学的影响 被引量:16

The effect of tetramethylpyrazine on the pharmacokinetics of intragastrically administered cyclosporine A in rats
暂未订购
导出
摘要 目的 研究中药成分川芎嗪(TMP)对大鼠灌服环孢素A(CsA)药代动力学的影响。方法 40只雄性SD大鼠按体重进行随机区组设计,分为4组。试验d1,每只大鼠灌服CsA(10mg·kg^-1)后,于0,1,2,3,4,6,8,12,24,36和48h从尾静脉处采血0.2~0.25mL。然后各组大鼠从试验的d4到d8进行不同的预处理,即每日分别灌服蒸馏水、维拉帕米(Ver)、低剂量和高剂量的TMP。d9时各组大鼠单次合用CsA(10mg·kg-1)和上述的各种化合物后,按d1的时间点采样。用HPLC法测定全血中CsA的浓度,计算其主要药代动力学参数并进行统计学分析。结果 合用蒸馏水组的CsA药代动力学参数前后无显著性差异;Ver预处理并合用后,CsA的AUC0-48h和Cmax均显著增加(P〈0.01和P〈0.05),T1/2β显著延长(P〈0.05),CL显著降低(P〈0.05),而Tmax和V的变化无统计学差异。低剂量TMP预处理并合用后,CsA的AUC0-48h和Cmax有增加的趋势,但无统计学差异,其余药代动力学参数的变化也无统计学的差异。高剂量TMP预处理并合用后,CsA的AUC0-48h和Cmax均有显著的增加(P〈0.01),但其他药代动力学参数的变化无统计学差异。结论 高剂量的TMP能显著提高CsA的灌服生物利用度,但对CsA的体内消除过程几乎没有影响。 Aim To investigate the possible effect of tetramethylpyrazine (TMP), an active ingredient of a commonly used Chinese herb, on the pharmacokinetics of cyclosporine A (CsA) by intragastric administration in rats. Methods Forty male Sprague-Dawley rats were equally divided into four groups by randomized block design according to weight. On the first day, after each fasting rat was intragastrically administered CsA (10 mg ·kg^-1) , blood samples (0. 2 -0. 25 mL) were collected from the tail vein at0, 1, 2, 3, 4, 6, 8, 12, 24, 36 and 48 h. From day 4 to day 8, each group began to undergo different pretreatments with intragastric administration of water, verapamil (Ver) , low and high dose TMP, separately. On day 9, each group intragastrically co-administered CsA ( 10 mg·kg^-1 ) and different pretreatment compounds mentioned above, then blood samples were collected according to the schedule of the first day. The whole blood concentration of CsA was determined by HPLC. Main pharmacokinetic parameters were calculated and compared by statistic analysis. Results In the group of water pretreated and co-administrated with CsA, no significantly different pharmacokinetic parameters of CsA were found. After Ver pretreatment and co-administration with CsA, AUC0-48h and Cmax were increased significantly (P 〈 0.01 and P 〈 0.05) ; T1/2β and CL were markedly prolonged and decreased (P 〈 0.05 ); Tin.X and V were not apparently influenced. After low dose TMP pretreatment and coadministration with CsA, there was no significant difference in the pharmacokinetic parameters of CsA, in spite of the increasing trends of AUC0-48h and Cmax. After high dose TMP pretreatment and coadministration with CsA, AUC0-48h and Cmax of CsA were increased significantly (P 〈 0.01 ) , but there was no significant change in other parameters. Conclusion It was indicated that the high dose of TMP could apparently increase the intragastric absorption extent of CsA, while almost had no effect on its elimination process.
出处 《药学学报》 CAS CSCD 北大核心 2006年第9期882-887,共6页 Acta Pharmaceutica Sinica
基金 湖南省卫生厅资助项目(B2003-065)
关键词 P-糖蛋白 细胞色素P450 3A 环孢素A 川芎嗪 药代动力学 高效液相色谱 P-glycoprotein CYP3A cyclosporine A tetramethylpyrazine pharmacokinetics HPLC
  • 相关文献

参考文献6

二级参考文献64

  • 1李晓明,吴谨绪,张连生,朱焕玲.环孢霉素 A 逆转复发难治性白血病多药耐药的临床研究[J].中华血液学杂志,1997,18(2):73-75. 被引量:23
  • 2吴雄飞,金锡御,刘宏,李为兵.缺血再灌流肾组织内皮素-1动态变化的实验研究[J].中华泌尿外科杂志,1997,18(7):404-407. 被引量:12
  • 3Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein) : recent advances andclinical relevance[ J ]. Clin Pharmacol Ther, 2004,75(1):13-33.
  • 4Zhang Y, Benet LZ. The gut as a barrier to drug absorption : combined role of cytochrome P450 3A and P-glycoprotein[ J ]. Clin Pharmacokinet, 2001,40 ( 3 ) :159 - 168.
  • 5Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications [ J ]. Clin Pharmacokinet, 2003,42( 1 ) :59 -98.
  • 6Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical,cellular, and pharmacological aspects of the multidrug transporter[J]. Annu Rev Pharmacol Toxicol, 1999,39 :361 - 398.
  • 7Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter [ J ].Annu Rev Pharmacol Toxicol , 2003,43:285 - 307.
  • 8Mizuno N, Niwa T, Yotsumoto Y, et al. Impact of drug transporter studies on drug discovery and development[J]. Pharmacol Rev, 2003,55(3):425 -461.
  • 9Lin JH, Lu AY. Interindividual variability in inhibition and induction of cytochrome P450 enzymes [ J ]. Annu Rev Pharmacol Toxicol , 2001,41:535 - 567.
  • 10Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications[ J ]. Clin Pharmacokinet, 2004,43 ( 9 ) :553 - 576.

共引文献86

同被引文献197

引证文献16

二级引证文献145

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部